| Sep 3 |
IBN Coverage: Clene (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases
|
| Sep 3 |
Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 23 |
IBN Coverage: Clene's (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers, Long-term Survival in ALS Trials
|
| Aug 13 |
IBN Coverage: Clene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative Conditions
|
| Aug 12 |
IBN Coverage: Clene (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode
|
| Aug 7 |
Clene GAAP EPS of -$1.06, revenue of $0.09M
|
| Aug 7 |
Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights
|
| Aug 6 |
Clene Announces New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS
|
| Aug 5 |
Clene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
|
| Jul 17 |
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
|
